Compare HNVR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HNVR | MOLN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 158.9M |
| IPO Year | 2022 | 2021 |
| Metric | HNVR | MOLN |
|---|---|---|
| Price | $21.70 | $3.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.50 | $8.38 |
| AVG Volume (30 Days) | ★ 4.7K | 3.3K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | $318.52 |
| P/E Ratio | $21.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.31 | $3.36 |
| 52 Week High | $24.36 | $5.36 |
| Indicator | HNVR | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 37.68 |
| Support Level | $21.60 | $4.04 |
| Resistance Level | $22.41 | $4.63 |
| Average True Range (ATR) | 0.50 | 0.24 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 49.24 | 27.69 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.